{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-011768","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.180884+00:00","generated_at":"2026-06-24T04:54:05.850841+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GlycoMimetics Q2 cash $60.2M; FDA clears GMI-1687 IND; uproleselan Phase 3 data expected mid-2023","bullets":["Cash and cash equivalents $60.2M as of June 30, 2022, down from $90.3M at Dec 31, 2021.","R&D expenses $8.0M (down from $10.2M YoY) due to lower uproleselan trial costs after enrollment ended.","G&A expenses $5.5M (up from $4.2M) for commercial start-up costs for uproleselan.","FDA cleared IND for GMI-1687 in sickle cell disease; company seeks licensing partner.","Phase 3 uproleselan trial (n=388) on track; survival events trigger expected mid-2023 with top-line data soon after."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-011768","json":"https://secwatch.observer/filing/0001558370-22-011768.json","markdown":"https://secwatch.observer/filing/0001558370-22-011768.md","text":"https://secwatch.observer/filing/0001558370-22-011768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837022011768/0001558370-22-011768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837022011768/glyc-20220803x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:54:05.850841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}